latest news releases from the newsroom
TG Therapeutics, Inc.
Manhattan Pharmaceuticals to Voluntarily Withdraw Its American Stock Exchange Common Stock Listing
NEW YORK, Feb. 22, 2008 (PRIME NEWSWIRE) -- Manhattan Pharmaceuticals, Inc. (AMEX:MHA) today announced that it has formally notified the American Stock Exchange ("AMEX") that it intends to voluntarily delist its common stock from AMEX. The company expects that the delisting will become effective within the next 25 calendar days. The company had been notified by AMEX on December 3, 2007, that failure to regain compliance with AMEX's listing requirements by April 16, 2008, will likely result in AMEX's staff initiating delisting proceedings pursuant to Section 1009 of the AMEX Company Guide. As the company could not ensure that it would meet such listing requirements, and in order to close on the joint venture transaction it recently entered into with Nordic Biotech Advisors ApS (Nordic) for the development and commercialization of Hedrin, the company's novel, non-insecticide treatment for head lice, the company determined to delist its common stock from AMEX.
Independent Bank Corp.
Independent Bank Corp. First Quarter Earnings Press Release and Conference Call Announcement
ROCKLAND, Mass., Feb. 22, 2008 (PRIME NEWSWIRE) -- Independent Bank Corp. (Nasdaq:INDB), parent of Rockland Trust Company, will release its first quarter earnings press release upon the close of business on Monday, May 5, 2008. It will host its quarterly conference call to discuss first quarter results on Monday, May 5, 2008, at 4:30 PM Eastern Time. Telephonic access will be available by dial-in at 800-860-2442 reference: INDB. A replay of the call will be available by calling 877-344-7529, Replay Passcode: 416741#, which will be available until May 12, 2008 at 11:59 PM.
Aastrom Biosciences, Inc.
Aastrom Biosciences Intends to Seek Shareholder Approval to Grant Board Authority to Amend Restated Articles of Incorporation
ANN ARBOR, Mich., Feb. 22, 2008 (PRIME NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading regenerative medicine company, today announced that the Company intends to seek shareholder approval to authorize the Board of Directors to amend Aastrom's Restated Articles of Incorporation to execute a reverse split of the Company's issued and outstanding common stock if they determine it is in the best interests of Aastrom and its shareholders. The Board would be authorized to execute the reverse split at any time within four weeks after the date of shareholder approval, at any whole number ratio between one for five and one for fourteen, with the exact exchange ratio and timing of the reverse stock split (if at all) to be determined at the discretion of the Board.
The National Research Fund for Tick-Borne Diseases, Inc.
Research Foundation for Tick-Borne Diseases to Fund Studies of Neurological and Immunological Mechanisms in Lyme Disease
WILTON, Conn., Feb. 22, 2008 (PRIME NEWSWIRE) -- The National Research Fund for Tick-Borne Diseases, Inc. (NRFTD), the nation's only non-profit organization dedicated primarily to funding scientific research in the rapidly expanding field of tick-borne infections, has announced the award of four grants totaling $344,000 for basic and translational research in Lyme disease. The two largest projects will focus on the pathogenesis of the illness. "Our goal this year was to fund research with maximum translational value to patients," said Carl Brenner of the NRFTD's Research Board. "Special emphasis was placed on proposals that showed particular promise for accelerating the transfer of findings to clinical application."
The First of Long Island Corporation
The First of Long Island Corporation Announces Additional Stock Repurchase Plan
GLEN HEAD, N.Y., Feb. 22, 2008 (PRIME NEWSWIRE) -- The Board of Directors of The First of Long Island Corporation (Nasdaq:FLIC) approved an additional stock repurchase plan which authorizes the Corporation to purchase from time to time in market or private transactions up to 200,000 shares of the Corporation's common stock. The stock purchases will be financed through available corporate cash. This is a continuation of the Corporation's stock repurchase program which began in 1988.